Product
TSHA-102
2 clinical trials
1 indication
Indication
Rett SyndromeClinical trial
Open-label, Randomized, Dose-escalation and Dose-expansion Study of the Safety and Preliminary Efficacy of a Single Intrathecal Administration of TSHA-102, an AAV9-Delivered Gene Therapy, in the Treatment of Adult Females With Rett SyndromeStatus: Recruiting, Estimated PCD: 2024-11-08
Clinical trial
A Multicenter, Open Label, Randomized, Dose-Escalation and Dose-Expansion Study of the Safety, Tolerability, and Efficacy of a Single Intrathecal Administration of TSHA-102, an AAV9-Delivered Gene Therapy, for the Treatment of Pediatric Females With Rett SyndromeStatus: Recruiting, Estimated PCD: 2028-11-02